|
Market Cap (5-Jun) $23,964,560 (896th) |
Close (30-Jun) $0.043 |
Volume (30-Jun) 1,415,719 |
Shortsold (5-Nov) 11,657 (0.00%) (566th) |
|
52w High $0.135 |
52w Low $0.043 |
P/E - |
EPS -0.02 |
NOX released this announcement to the ASX on 15 November 2021, 9:10. The announcement is marked as price sensitive, and is 4 page(s) in length and 326.61kb in size.
You can view all announcements from NOX and see how they appear on a price chart on the announcements page.
At the date of this announcement, NOX was 0.105% short sold according to ASIC data. It was ranked the 460th most shorted stock on the ASX. It remains ranked 566th as of the latest reported data (05 November 2025).
| Other Recent Announcements from NOX | |
|---|---|
| Change of Director's Interest Notice - FB | 29 June 2023, 12:08 |
| Change of Director's Interest Notice - FB | 19 June 2023, 19:08 |
| Change of Director's Interest Notice - BP | 19 June 2023, 19:08 |
| Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial | 15 November 2021, 9:10 |
| DARRT-2 Trial Commences in the U.S. | 4 November 2021, 8:33 |
| Unlisted Options Expiring on 30 November 2021 | 29 October 2021, 14:10 |
| Veyonda and Opdivo IONIC Study First Patient Dosed | 26 October 2021, 8:34 |
You must be logged in to post a reply.
Noxopharm 